Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of ABBV-951 in Parkinson's Disease
NCT03781167Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2019
- Primary completion
- Aug 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of vyalev in Parkinson's disease (PD), sponsored by AbbVie Inc. Primary endpoints: Number of Participants With Adverse Events up to 480 days, Number of Participants With Adverse Events of Special Interest up to 480 days and 6 more. Started Apr 2019; status: completed.
02
Drugs
vyalev
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03781167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781167.